Suppr超能文献

静脉注射和口服布尼洛尔(Kö 1366)的降压作用

Antihypertensive effect of intravenously and orally administered bunitrolol (Kö 1366).

作者信息

Okabayashi T, Naito S, Arakawa K

出版信息

Arzneimittelforschung. 1979;29(9):1417-21.

PMID:42418
Abstract
  1. Hypotensive effect of O-[3-(tert, butylamino-2-hydroxypropoxy]-benzonitrile hydrochloride (bunitrolol, Kö 1366) was examined by intravenous administration of 5 mg to 20 cases of essential hypertension and by longterm oral administration of 15-30 mg to 27 cases of essential hypertension. 2. It was found that bunitrolol given either i.v. or p.o., produced a significant decrease of systolic, diastolic and mean blood pressure at rest. 3. Inhibitory effect of bunitrolol on exercise-induced increase of blood pressure was remarkable, while there was little inhibitory effect on the cold pressor-induced one. 4. Bunitrolol decreased blood pressure and lowered plasma renin activity in high renin hypertensive patients, suggesting that the hypotensive mechanism based, at least in part, on its capacity of inhibiting renin secretion. 5. However, the main hypotensive mechanism of bunitrolol seemed, in the case of i.v. use, related to the cardiac inhibitory action. Regarding the hypotensive mechanism of this drug in the long-term use, further investigation will be required.
摘要
  1. 通过对20例原发性高血压患者静脉注射5毫克以及对27例原发性高血压患者长期口服15 - 30毫克盐酸O - [3 -(叔丁氨基 - 2 - 羟基丙氧基)]苯甲腈(布尼洛尔,Kö 1366),研究其降压作用。2. 发现静脉注射或口服布尼洛尔均可使静息时的收缩压、舒张压和平均血压显著下降。3. 布尼洛尔对运动诱发的血压升高有显著抑制作用,而对冷加压诱发的血压升高抑制作用较小。4. 布尼洛尔可降低高肾素型高血压患者的血压并降低血浆肾素活性,提示其降压机制至少部分基于抑制肾素分泌的能力。5. 然而,静脉注射时布尼洛尔的主要降压机制似乎与心脏抑制作用有关。关于该药物长期使用时的降压机制,还需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验